Table 4

Comparison of the age-standardised prevalence of epiretinal membrane in the Jiangning Eye Study and other population-based eye studies using the WHO world population

StudyCountry, year (s) conductedAge, range (years)Population at riskCrude prevalence (%) in all participantsCrude prevalence (%) in participants aged 50+ yearsAge-standardised prevalence (%) (95% CI) in participants aged 50+ years*
Beaver Dam Eye Study2USA, 1988–199043–84480211.8NANA
Blue Mountains Eye Study3Australia, 1992–199349+34907.07.05.5 (4.7 to 6.2)
Melbourne VIP7Australia, 1992, 199740+43136.07.97.4 (6.4 to 8.3)
Hisayama Study5Japan, 199840+17654.04.63.5 (2.6 to 4.5)
Los Angeles Latino Eye Study6USA, 2000–200340+598218.523.824.0 (22.6 to 25.4)
Beijing Eye Study10China, 200140+43782.2NANA
Singapore Malay Eye Study9Singapore, 2004–200640–80326511.814.9†13.4 (12.1 to 14.8)†
Melbourne Collaborative Cohort Study16Australia, 2003–200740+21 2418.98.97.8 (7.4 to 8.1)
Handan Eye Study11China, 2006–200730+65653.44.96.7 (5.9 to 7.4)
Singapore Indian Eye Study14Singapore, 2007–200940–80332810.212.6†12.1 (10.8 to 13.4)†
Beixinjing Block Study15China, 2010–201160+33261.01.0‡1.0 (0.7 to 1.3)‡
Jiangning Eye StudyChina, 2012–201350+20058.48.47.6 (6.5 to 8.8)
  • *Age standardisation to the WHO world population, the 2012 revision.

  • †Prevalence of epiretinal membrane in participants aged 50–80 years.

  • ‡Prevalence of epiretinal membrane in participants aged 60+ years.